AZ14289671是一种高度选择性和穿透血脑屏障的不可逆转的TKI,针对EGFRExon20插入
Aisha M Swaih1, Sara Talbot1, Adriana Savoca2
1Bioscience, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK.
一种名为AZ14289671的新药有望治疗具有特定EGFR突变的非小细胞肺癌 (NSCLC). 这种强大的氨酸激酶抑制剂 (TKI) 有效地向瘤,包括大脑转移,同时保护健康细胞.
科学领域:
- 癌症学
- 分子生物学
- 药理学
背景情况:
- 非小细胞肺癌 (NSCLC) 具有表皮生长因子受体 (EGFR) 插入外因子20 (EGFRExon20Ins) 突变是一个治疗挑战.
- 目前对EGFRExon20InsNSCLC的治疗方法,尤其是大脑转移,有效性有限.
- 迫切需要新型向疗法,如氨酸激酶抑制剂 (TKI).
研究的目的:
- 评估新型TKIAZ14289671在NSCLC中对EGFRExon20Ins突变的临床前疗效.
- 评估药物的有效性,选择性和穿透血脑屏障的能力.
- 为了确定AZ14289671对EGFRExon20Ins的NSCLC患者的改善结果的潜力.
主要方法:
- 使用EGFRExon20Ins突变的NSCLC细胞系进行临床前评估.
- 在细胞系衍生异种移植 (CDX) 和患者衍生异种移植 (PDX) 模型中进行评估.
- 对信号通路抑制,瘤回归和血脑屏障透的评估.
主要成果:
- 在EGFRExon20Ins模型中,AZ14289671表现出强烈的信号通路抑制.
- 在多个EGFRExon20Ins模型中观察到高度持续的瘤回归.
- 药物对野生型 (WT) EGFR的活性很小,并成功穿过血脑屏障.
- 临床前模型显示显著的瘤回归和持续的信号通路抑制.
结论:
- AZ14289671是一种强效,有选择性,可口服的TKI,向EGFRExon20Ins突变.
- 它穿透血脑屏障的能力为治疗NSCLC的大脑转移提供了潜力.
- 在EGFRExon20Ins突变的NSCLC患者中,AZ14289671是一个有前途的治疗候选药物.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
